Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Next Previous
Trial Profile

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ 79635322 (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms TRIlogy-3
  • Sponsors Janssen Research & Development

Most Recent Events

  • 17 Feb 2026 Status changed from not yet recruiting to recruiting.
  • 16 Jan 2026 Planned initiation date changed from 24 Feb 2026 to 20 Feb 2026.
  • 07 Jan 2026 Planned initiation date changed from 17 Mar 2026 to 24 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top